Maximum quantity allowed is 999
请选择数量
CAS RN: 16676-29-2 | 产品编码: N1176
Naltrexone Hydrochloride
产品编码 | N1176 |
纯度/分析方法 | >98.0%(GC)(HPLC) |
分子式/分子量 | C__2__0H__2__3NO__4·HCl = 377.87 |
外观与形状(20°C) | 固体 |
储存温度 | 冷藏 (0-10°C) |
储存在惰性气体下 | 存放于惰性气体之中 |
应避免的情况 | 湿气 (吸湿),加热 |
包装和容器 | 1G-Glass Bottle with Plastic Insert (查看图片), 250MG-Glass Bottle with Plastic Insert (查看图片) |
CAS RN | 16676-29-2 |
Reaxys-RN | 3580333 |
PubChem物质ID | 468592499 |
MDL编号 | MFCD00069324 |
技术规格
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Water | max. 11.0 % |
物性(参考值)
熔点 | 178 °C |
水溶性 | 可溶 |
GHS
象形图 | |
信号词 | Warning |
危险性说明 | H302 : Harmful if swallowed. |
防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相关法规
RTECS# | QD2160000 |
运输信息
HS编码* | 2939.19-000 |
应用
Naltrexone Hydrochloride: A Long Acting Competitive Peripheral μ-Opioid Antagonist
Naltrexone hydrochloride, a long acting competitive peripheral μ-opioid antagonist, is a synthetic congener of opioid analgesics with little or no μ-opioid agonist properties.1) It is used for the treatment of opioid dependence and opioid-induced constipation, and is also used for alcohol dependence in US and EU.2,3) Recently, μ-opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. Therefore, the μ-opioid antagonist naltrexone has received attention as a new anticancer agent with few side-effects (low-dose naltrexone, LDN).4,5) (The product is for research purpose only.)
References
- 1) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
- 2) Alteration of ethanol self-administration by naltrexone
- 3) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence (a review)
- 4) The opioid growth factor-opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease (a review)
- 5) Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy (a review)
产品文档 (部分产品的分析图谱无法提供,敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助,请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注:该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉,您搜索的分析图谱无法提供。